Crossmark Global Holdings, Inc. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Crossmark Global Holdings, Inc. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$445
-4.5%
8,199
+7.0%
0.01%0.0%
Q2 2023$466
+12.3%
7,666
+0.1%
0.01%0.0%
Q1 2023$415
+2.5%
7,656
-0.1%
0.01%0.0%
Q4 2022$405
-99.9%
7,662
+9.8%
0.01%
+11.1%
Q3 2022$325,000
-4.4%
6,977
+17.3%
0.01%0.0%
Q2 2022$340,0005,9500.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders